Friday, 16 October 2026European Markets

NYRSTAR Stock Was 10.36% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with NYRSTAR (NYR.BR) jumping 10.36% to €0.12 on Friday while BEL 20 slid 1.34% to €3,352.93.

NYRSTAR's last close was €0.11, 47.14% below its 52-week high of €0.21.

About NYRSTAR

Nyrstar NV does not have significant operations. Previously, it was engaged in the mining, smelting, and producing of zinc, lead, and other base and precious metals primarily in Europe, Australia, Canada, and the United States. Nyrstar NV was founded in 2007 and is based in Balen, Belgium.

Earnings Per Share

As for profitability, NYRSTAR has a trailing twelve months EPS of €-0.01.

Volatility

NYRSTAR's last week, last month's, and last quarter's current intraday variation average was a positive 0.02%, a negative 0.99%, and a positive 2.89%.

NYRSTAR's highest amplitude of average volatility was 4.79% (last week), 2.85% (last month), and 2.89% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NYRSTAR's stock is considered to be overbought (>=80).

Moving Average

NYRSTAR's value is way under its 50-day moving average of €0.13 and way below its 200-day moving average of €0.14.

More news about NYRSTAR (NYR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com